E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion

被引：0
|
作者：
Hilary Glen
Susan Mason
Hitesh Patel
Kenneth Macleod
Valerie G Brunton
机构：
[1] Beatson Institute for Cancer Research,Edinburgh Cancer Research Centre
[2] University of Edinburgh,undefined
来源：
BMC Cancer | / 11卷
关键词：
Fibroblast Growth Factor Receptor; Wound Healing Assay; Platelet Derive Growth Factor Receptor; U2OS Cell; Lymphatic Vessel Density;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor Sunitinib
    Huang, Qiang
    Zhou, Changhua
    Chen, Xiao
    Dong, Bing
    Chen, Siqi
    Zhang, Ning
    Liu, Yawei
    Li, Anrong
    Yao, Meicun
    Miao, Ji
    Li, Qing
    Wang, Zhong
    [J]. PLOS ONE, 2015, 10 (10):
  • [42] A Phase I Study of the Multi-Targeted Tyrosine Kinase Inhibitor Cabozantinib in Patients with Acute Myeloid Leukemia
    Fathi, Amir T.
    Blonquist, Traci M.
    Levis, Mark J.
    Hernandez, Daniela
    Ballen, Karen K.
    Avigan, David E.
    Joyce, Robin
    McMasters, Malgorzata
    Logan, Emma
    Hobbs, Gabriela S.
    Brunner, Andrew M.
    Connolly, Christine
    Perry, Ashley M.
    Joseph, Christelle
    Som, Tina T.
    Ramos, Aura Y.
    Neuberg, Donna S.
    Amrein, Philip C.
    [J]. BLOOD, 2016, 128 (22)
  • [43] MEDI 301-ABT-869, an orally active multi-targeted receptor tyrosine kinase inhibitor
    Dai, Yujia
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2006, 232
  • [44] Multi-targeted tyrosine kinase inhibitor Cabozantinib as a therapeutic agent in MET-overexpressing gastric cancer
    Choi, Audrey H.
    Lu, Jianming
    Lee, Sangjun
    Chu, Peiguo
    Chung, Vincent
    Lin, Ren-Jang
    Kim, Joseph
    Chao, Joseph
    [J]. CANCER RESEARCH, 2015, 75
  • [45] Subgroup analyses of a phase 1/2 study of lenvatinib (E7080), a multitargeted tyrosine kinase inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ikeda, Masafumi
    Ikeda, Kenji
    Kudo, Masatoshi
    Osaki, Yukio
    Okusaka, Takuji
    Tamai, Toshiyuki
    Suzuki, Takuya
    Hisai, Takashi
    Miyagishi, Hideaki
    Okita, Kiwamu
    Kumada, Hiromitsu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [46] Plasma biomarkers predictive for disease control duration in the phase I study of E7080, a multitarget kinase inhibitor
    Yamamoto, N.
    Yamada, Y.
    Nokihara, H.
    Goto, Y.
    Tanioka, M.
    Yamada, K.
    Koizumi, F.
    Koyama, N.
    Tamura, T.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [47] The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
    Zhou, Yan
    Zhang, Yuanliang
    Zou, Hanbing
    Cai, Ning
    Chen, Xiaojing
    Xu, Longmei
    Kong, Xianming
    Liu, Peifeng
    [J]. SCIENTIFIC REPORTS, 2015, 5
  • [48] The multi-targeted tyrosine kinase inhibitor vandetanib plays a bifunctional role in non-small cell lung cancer cells
    Yan Zhou
    Yuanliang Zhang
    Hanbing Zou
    Ning Cai
    Xiaojing Chen
    Longmei Xu
    Xianming Kong
    Peifeng Liu
    [J]. Scientific Reports, 5
  • [49] Multi-targeted tyrosine kinase inhibitors and VEGFR-targeting agents
    Eckhardt, SG
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : 20 - 20
  • [50] Preclinical discovery research of E7080, an inhibitor of Vascular Endothelial Growth Factor Receptor (VEGFR) family of tyrosine kinases
    Funahashi, Yasuhiro
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2010, 112 : 33P - 33P
12345